Sen. Grassley Seeks Info On Prodisc Researchers

Law360, New York (February 27, 2008, 12:00 AM EST) -- Concerned over reports of impropriety, a prominent Republican senator is reportedly demanding answers from the U.S. Food and Drug Administration and the maker of Prodisc over rumors that some doctors involved in the clinical research of the synthetic spinal disk stood to gain financially from the medication's success.

Sen. Charles E. Grassley (R-Iowa), the ranking member of the Senate Finance Committee, shipped a letter off to the FDA and Synthes on Wednesday, asking for information about what regulators knew about the clinical investigators prior to Prodisc's...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.